Phase 3 study on Alzheimer’s disease (ALZ)2019-04-08T11:38:44+00:00

Project Description

Phase 3 study on Alzheimer’s disease (ALZ)


Alzheimer’s disease is an irreversible progressive brain disorder that slowly destroys memory and thinking skills and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia in elderly population. Dementia is not a normal part of aging but is more common as people grow older.

As of today, there isn’t a treatment that shows a real efficacy in treating this disease, and the causes are still not fully known.

In this perspective, R.G.L has been mandated by a biotechnology company to lead an international and competitive phase 3 study in Israel to prove the efficacy and the safety of a new drug, based on a new hypothesis mode of action that affects the early chain of the neurodegeneration process.


  • To open Israel has a participating country in this trial,
  • To find 3 medical centers with a high rate of patients recruitment, 
  • To sign with all 3 centers a Clinical Trial Agreement and negotiate a budget per patient according to Sponsor’s guidelines and recommendations, 
  • To obtain Local Ethical Committee approvals in the conduct of the Trial, 
  • To recruit at least 18 patients in 4 months, 

Want To Work With Us?


Contact Us